

Clinical Oversight Review Board (CORB) Criteria for Prescribing Vutrisiran (Amvuttra)

Non-Formulary **Vutrisiran (Amvuttra)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by a neurologist
- Patient is 18 years or older
- Patient has a diagnosis of Neuropathic Heredofamilial Amyloidosis
- Documented confirmed transthyretin (TTR) mutation from genetic testing
- Patient does not have end-stage renal disease (chronic kidney disease stage 5)
- Patient has not had a prior liver transplant
- Patient does not have severe hepatic impairment [alanine transaminase (ALT) greater than 2.5 times the upper limit of normal] and/or cirrhosis
- Patient does not have hepatitis B or C infection, human immunodeficiency virus (HIV) infection, or active malignancy
- Patient has been reviewed by the Kaiser Permanente Interregional Consultative Physician Panel, with recommendation to use medication